X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (32) 32
animals (23) 23
mice (18) 18
phosphorylation (13) 13
biochemistry (12) 12
biochemistry & molecular biology (11) 11
proteins (11) 11
cell biology (10) 10
cell cycle (10) 10
oncology (10) 10
beer (9) 9
chemistry (9) 9
enzymology (9) 9
human necessities (9) 9
hygiene (9) 9
investigating or analysing materials by determining theirchemical or physical properties (9) 9
male (9) 9
measuring (9) 9
medical or veterinary science (9) 9
metallurgy (9) 9
microbiology (9) 9
mutation or genetic engineering (9) 9
physics (9) 9
preparations for medical, dental, or toilet purposes (9) 9
signal transduction (9) 9
spirits (9) 9
testing (9) 9
vinegar (9) 9
wine (9) 9
compositions thereof (8) 8
culture media (8) 8
microorganisms or enzymes (8) 8
nuclear proteins - metabolism (8) 8
propagating, preserving or maintaining microorganisms (8) 8
cell line (7) 7
mitosis (7) 7
proteolysis (7) 7
analysis (6) 6
anaphase-promoting complex (6) 6
cancer (6) 6
cell line, tumor (6) 6
hela cells (6) 6
medicine, research & experimental (6) 6
multiple myeloma (6) 6
mutation (6) 6
protein binding (6) 6
tumors (6) 6
ubiquitin (6) 6
apoptosis (5) 5
cell cycle proteins (5) 5
cell cycle proteins - metabolism (5) 5
cells, cultured (5) 5
female (5) 5
flow cytometry (5) 5
immunoblotting (5) 5
ligases (5) 5
mice, knockout (5) 5
nih 3t3 cells (5) 5
research (5) 5
specific therapeutic activity of chemical compounds ormedicinal preparations (5) 5
survival (5) 5
abridged index medicus (4) 4
adaptor proteins, signal transducing (4) 4
cell cycle - physiology (4) 4
cell cycle proteins - genetics (4) 4
chemotherapy (4) 4
cos cells (4) 4
cyclin b1 (4) 4
enzyme inhibitors - pharmacology (4) 4
f-box proteins - genetics (4) 4
f-box proteins - metabolism (4) 4
gene expression (4) 4
localization (4) 4
middle aged (4) 4
mitosis - physiology (4) 4
molecular sequence data (4) 4
protein structure, tertiary (4) 4
proto-oncogene proteins - metabolism (4) 4
skp cullin f-box protein ligases - metabolism (4) 4
time factors (4) 4
ubiquitin - metabolism (4) 4
ubiquitination (4) 4
adaptor proteins, signal transducing - metabolism (3) 3
adult (3) 3
aged (3) 3
amino acid sequence (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
article (3) 3
binding (3) 3
biology (3) 3
blotting, western (3) 3
care and treatment (3) 3
cell death (3) 3
cell survival (3) 3
clinical trials (3) 3
compositions or test papers therefor (3) 3
condition-responsive control in microbiological orenzymological processes (3) 3
degradation (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 5, pp. 569 - 576
Abstract Introduction Human epidermal growth factor receptor 2 (HER2) amplification is present in a subgroup of gastroo-esophageal cancers (GCs). HER2... 
Hematology, Oncology and Palliative Medicine | Lapatinib | HER2 | Gastric cancer | EGFR | SURVIVAL | PLACEBO | TRASTUZUMAB | OPEN-LABEL | KINASE INHIBITOR | CHEMOTHERAPY | PACLITAXEL | BREAST-CANCER | SUPPORTIVE CARE | ONCOLOGY | ADVANCED GASTRIC-CANCER | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Protein Kinase Inhibitors - adverse effects | Esophageal Neoplasms - pathology | Fluorouracil - administration & dosage | Time Factors | Esophageal Neoplasms - mortality | Adult | Female | Quinazolines - administration & dosage | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Signal Transduction | Deoxycytidine - administration & dosage | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Esophageal Neoplasms - enzymology | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Germany | Adenocarcinoma - mortality | Antimitotic agents | Epidermal growth factor | Clinical trials | Product development | Metastasis | Antineoplastic agents | Esophageal cancer | Index Medicus
Journal Article
Journal Article
Science, ISSN 0036-8075, 12/2017, Volume 358, Issue 6367, p. eaan4368
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug... 
REFINEMENT | PROTEIN | CHEMICAL PROTEOMICS | INHIBITOR SELECTIVITY | DATA QUALITY | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | INTEGRATIVE GENOMICS VIEWER | SALT-INDUCIBLE KINASES | CANCER | COMPREHENSIVE ANALYSIS | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Cytokines - metabolism | Humans | Drug Discovery - methods | Antineoplastic Agents - chemistry | Molecular Targeted Therapy | Xenograft Model Antitumor Assays | Leukemia, Myeloid, Acute - enzymology | Protein Kinase Inhibitors - chemistry | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Proteomics - methods | Salts | Target recognition | Lung cancer | Selectivity | Drug development | Cancer therapies | Signal transduction | Biomolecules | Protein-tyrosine kinase | Tyrosine | Medical research | Imatinib | Decision making | Medical treatment | Mass spectroscopy | Tumor necrosis factor-α | Embryos | Bruton's tyrosine kinase | Mode of action | Side effects | Inhibitors | Interleukin 10 | Affinity | Drug discovery | Mass spectrometry | Acute myeloid leukemia | Drugs | Deregulation | Leukemia | Interleukin | Medical services | Clinical trials | Leucine | Kinases | Biological effects | Epidermal growth factor | Salt-inducible kinase | Xenografts | Cell survival | Epidermal growth factor receptors | Research & development--R&D | Therapeutic applications | Myeloid leukemia | Markers | Data processing | Lead compounds | Leucine zipper proteins | Signaling | Proteomics | Cancer | Index Medicus
Journal Article
Journal Article
Hypertension, ISSN 0194-911X, 01/2007, Volume 49, Issue 1, pp. 201 - 208
Journal Article
International Review of Cell and Molecular Biology, ISSN 1937-6448, 01/2019, Volume 343, pp. 219 - 297
Multiple myeloma (MM) is the second most common hematological malignancy and results from the clonal amplification of plasma cells. Despite recent advances in... 
PI3K | Ubiquitin proteasome system | Multiple myeloma | mTOR inhibitors | S6K | Akt | mTOR signaling | mTORC2 | PI3K inhibitors | mTORC1 | Proteasome inhibitors
Conference Proceeding
Nature Medicine, ISSN 1078-8956, 07/2016, Volume 22, Issue 7, pp. 735 - 743
Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and pomalidomide, are key treatment modalities for hematologic... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | THALIDOMIDE | CEREBLON | MULTIPLE-MYELOMA CELLS | CANCER-THERAPY | CELL BIOLOGY | 5Q DELETION | LENALIDOMIDE | DEXAMETHASONE COMBINATION | MYELODYSPLASTIC SYNDROMES | T-CELLS | E3 UBIQUITIN LIGASE | Cell Cycle Proteins - drug effects | Oncogene Proteins - genetics | Peptide Hydrolases - genetics | Humans | Peptide Hydrolases - drug effects | Thalidomide - pharmacology | RNA, Messenger - metabolism | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Basigin - genetics | Basigin - drug effects | Cell Cycle Proteins - genetics | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Peptide Hydrolases - metabolism | RNA, Messenger - drug effects | Myelodysplastic Syndromes - metabolism | Teratogenesis - genetics | Cell Cycle Proteins - metabolism | Oncogene Proteins - metabolism | Multiple Myeloma - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Oncogene Proteins - drug effects | Signal Transduction - drug effects | Basigin - metabolism | Myelodysplastic Syndromes - genetics | Immunologic Factors - pharmacology | Multiple Myeloma - genetics | Teratogenesis - drug effects | Cellular proteins | Immunity | Carcinogenesis | Health aspects | Patient outcomes | Risk factors | Proteins | Drug therapy | Multiple myeloma | Tumors | Index Medicus
Journal Article
EMBO reports, ISSN 1469-221X, 03/2018, Volume 19, Issue 3, pp. e44799 - n/a
Journal Article
Journal Article
Nature Cell Biology, ISSN 1465-7392, 01/2013, Volume 15, Issue 1, pp. 72 - 81
Journal Article